Table 3 Overview of previous studies that investigated the differential response of HER2-positive classes to therapy
From: HER2 expression in breast cancer: evidence gaps and challenges
Neoadjuvant Setting | Study Title | Rate of pathologic complete response | P value | ||
|---|---|---|---|---|---|
Overall | HER2 IHC 3 + | HER2 IHC 2 + /ISH positive | |||
Yan et al.13 | Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer | 37.2% (110/296) | 41.4% (99/139) | 19.3% (11/75) | 0.003 |
Krystel-Whittemore et al.14 | Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy | 59% (330/560) | 67% (303/455) | 17% (12/76) | <0.001 |
Rakha et al.15 | Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio≥ 2.0, HER2 copy number< 4.0 signals/cell) cases | 25% (184/749) | 54% (79/146) | 19% (35/180) | <0.001 |
Xu et al.16 | HER2 protein expression level is positively associated with the efficacy of neoadjuvant systemic therapy in HER2-positive breast cancer | 43.7% (73/167) | 47.9% (67/140) | 22.2% (6/27) | 0.014 |
Zhao et al.17 | HER2 immunohistochemistry staining positivity is strongly predictive of tumour response to neoadjuvant chemotherapy in HER2-positive breast cancer | 64.5% (49/76) | 80% (40/49) | 34% (9/40) | <0.001 |
Chen et al.18 | Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer | 74/181 (40.9%) | 46% | 25% | 0.016 |
Atallah et al.19 | Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level | 26% (194/751) | 57% (88/155) | 22% (35/162) | 0.001 |
Chen et al.20 | Differences between the efficacy of HER2(2 + ) /FISH-positive and HER2 (3 + ) in breast cancer during dual-target neoadjuvant therapy | 59.8% | 63.3% | 41.7% | <0.05 |
Jiao et al.21 | Comparison of the Response to Neoadjuvant Therapy Between Immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH+ Early-Stage Breast Cancer: A Retrospective Multicentre Cohort Study | 35.5% | 40% | 18% | <0.001 |
Winer, Ruth et al.22 | Immunohistochemical Status Predicts Pathologic Complete Response to Neoadjuvant Therapy in HER2-Overexpressing Breast Cancers | 49% | 54% | 22% | <0.001 |
